Compare FERG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FERG | NTRA |
|---|---|---|
| Founded | 1887 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4B | 45.3B |
| IPO Year | 2024 | 2015 |
| Metric | FERG | NTRA |
|---|---|---|
| Price | $236.45 | $327.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $268.54 | $259.07 |
| AVG Volume (30 Days) | ★ 3.7M | 1.4M |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 9.26 | 0.65 |
| EPS | ★ 5.56 | N/A |
| Revenue | ★ $30,762,000,000.00 | $210,939,000.00 |
| Revenue This Year | $7.98 | $18.08 |
| Revenue Next Year | $5.86 | $19.65 |
| P/E Ratio | $43.57 | ★ N/A |
| Revenue Growth | ★ 3.80 | N/A |
| 52 Week Low | $207.64 | $157.43 |
| 52 Week High | $271.64 | $333.56 |
| Indicator | FERG | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 68.06 |
| Support Level | $219.86 | $187.64 |
| Resistance Level | $268.63 | N/A |
| Average True Range (ATR) | 6.55 | 10.93 |
| MACD | -1.75 | 1.95 |
| Stochastic Oscillator | 2.87 | 90.53 |
Ferguson distributes plumbing and HVAC products to North American repair, maintenance, and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 37,000 suppliers. Ferguson engages customers through approximately 1,700 North American branches, over the phone, online, and in residential showrooms. The firm sold its UK business in 2021 and is now solely focused on the North American market.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.